Description: Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech’s current pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the U.S., Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech’s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA; US), STADA Arzneimittel AG (EU and select other territories), Fuji Pharma Co., Ltd (TSE: 4554; Japan), Cipla/Cipla Gulf/Cipla Med Pro (NSE: CIPLA; Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (SWX:DKSH; Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (NASDAQ and TASE: KMDA; Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (1795:TT; Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners.
Home Page: www.alvotech.com
ALVO Technical Analysis
Saemundargata 15-19
Reykjavik,
102
Iceland
Phone:
354 422 4500
Officers
| Name | Title |
|---|---|
| Mr. Robert Wessman | Founder & Exec. Chairman of Directors |
| Mr. Mark Levick | Chief Exec. Officer |
| Mr. Joel Morales | Chief Financial Officer |
| Mr. Sean Gaskell | Chief Technical Officer |
| Mr. Joseph E. McClellan | Chief Scientific Officer |
| Ms. Rose-Marie Ohlsson | Chief Information Officer |
| Ms. Sigridur Elin Gudlaugsdottir | VP of HR |
| Ms. Tanya Zharov | Deputy Chief Exec. Officer |
| Mr. Anil Okay | Chief Commercial Officer |
| Mr. Ming Li | Chief Strategy Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 47.8 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 20.6922 |
| IPO Date: | 2022-06-16 |
| Fiscal Year End: | December |
| Full Time Employees: | 784 |